



Universiteit
Leiden
The Netherlands

Quantification of myocardial creatine and triglyceride content in the human heart: precision and accuracy of in vivo proton magnetic resonance spectroscopy

Bakermans, A.J.; Boekholdt, S.M.; Vries, D.K. de; Reckman, Y.J.; Farag, E.S.; Heer, P. de; ...
; Nederveen, A.J.

Citation

Bakermans, A. J., Boekholdt, S. M., Vries, D. K. de, Reckman, Y. J., Farag, E. S., Heer, P. de, ... Nederveen, A. J. (2021). Quantification of myocardial creatine and triglyceride content in the human heart: precision and accuracy of in vivo proton magnetic resonance spectroscopy. *Journal Of Magnetic Resonance Imaging*, 54(2), 411-420.
doi:10.1002/jmri.27531

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3277421>

Note: To cite this publication please use the final published version (if applicable).

Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy

Adrianus J. Bakermans, PhD,^{1*}  S. Matthijs Boekholdt, MD, PhD,² Dylan K. de Vries, MD,³ Yolanda J. Reckman, MD,³ Emile S. Farag, MD, PhD,⁴ Paul de Heer, PhD,^{1,5} Laween Uthman, PhD,⁶ Simone W. Denis, BSc,⁷ Coert J. Zuurbier, PhD,⁶ Riekelt H. Houtkooper, PhD,⁷ David R. Koolbergen, MD, PhD,⁴ Jolanda Kluin, MD, PhD,⁴ R. Nils Planken, MD, PhD,¹ Hildo J. Lamb, MD, PhD,⁸ Andrew G. Webb, PhD,⁵ Gustav J. Strijkers, PhD,⁹ Daniel A. Beard, PhD,¹⁰ Jeroen A.L. Jeneson, PhD,¹¹ and Aart J. Nederveen, PhD¹

Background: Proton magnetic resonance spectroscopy (¹H-MRS) of the human heart is deemed to be a quantitative method to investigate myocardial metabolite content, but thorough validations of in vivo measurements against invasive techniques are lacking.

Purpose: To determine measurement precision and accuracy for quantifications of myocardial total creatine and triglyceride content with localized ¹H-MRS.

Study type: Test–retest repeatability and measurement validation study.

Subjects: Sixteen volunteers and 22 patients scheduled for open-heart aortic valve replacement or septal myectomy.

Field Strength/Sequence: Prospectively ECG-triggered respiratory-gated free-breathing single-voxel point-resolved spectroscopy (PRESS) sequence at 3 T.

Assessment: Myocardial total creatine and triglyceride content were quantified relative to the total water content by fitting the ¹H-MR spectra. Precision was assessed with measurement repeatability. Accuracy was assessed by validating in vivo ¹H-MRS measurements against biochemical assays in myocardial tissue from the same subjects.

Statistical Tests: Intrasession and intersession repeatability was assessed using Bland–Altman analyses. Agreement between ¹H-MRS measurements and biochemical assay was tested with regression analyses.

View this article online at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com/doi/10.1002/jmri.27531). DOI: 10.1002/jmri.27531

Received Dec 2, 2020, Accepted for publication Jan 11, 2021.

*Address reprint requests to: Adrianus J. Bakermans, PhD (senior author), Department of Radiology and Nuclear Medicine (Z0-180), Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. E-mail: a.j.bakermans@amsterdamumc.nl

Grant Support: Dr. Bakermans is supported by a Veni grant from the Netherlands Organisation for Scientific Research (NWO; project number 91617155). Part of this work was supported by a grant from the United States National Institutes of Health (NIH; R01 HL144657).

From the ¹Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands;

²Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ³Department of Experimental

Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ⁴Department of Cardiothoracic Surgery,

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ⁵C.J. Gorter Center for High Field MR, Department of

Radiology, Leiden University Medical Center, Leiden, The Netherlands; ⁶Laboratory of Experimental Intensive Care and Anesthesiology, Department of

Anesthesiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands;

⁷Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam

University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ⁸Department of Radiology, Leiden University Medical Center, Leiden, The

Netherlands; ⁹Biomedical Engineering and Physics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands;

¹⁰Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA; and ¹¹Neuroimaging Center, Department of

Neuroscience, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Additional supporting information may be found in the online version of this article

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Results: The intersession repeatability coefficient for myocardial total creatine content was 41.8% with a mean value of $0.083\% \pm 0.020\%$ of the total water signal, and 36.7% for myocardial triglyceride content with a mean value of $0.35\% \pm 0.13\%$ of the total water signal. Ex vivo myocardial total creatine concentrations in tissue samples correlated with the in vivo myocardial total creatine content measured with $^1\text{H-MRS}$: $n = 22$, $r = 0.44$; $P < 0.05$. Likewise, ex vivo myocardial triglyceride concentrations correlated with the in vivo myocardial triglyceride content: $n = 20$, $r = 0.50$; $P < 0.05$.

Data Conclusion: We validated the use of localized $^1\text{H-MRS}$ of the human heart at 3 T for quantitative assessments of in vivo myocardial tissue metabolite content by estimating the measurement precision and accuracy.

Level of Evidence: 2

Technical Efficacy Stage: 2

J. MAGN. RESON. IMAGING 2021;54:411–420.

The first proton magnetic resonance spectra ($^1\text{H-MRS}$) of the human heart were published more than 25 years ago.¹ With this noninvasive technique, metabolically and (patho)physiologically relevant compounds such as creatine and triglyceride can be detected in in vivo myocardial tissue.² The amplitudes of the acquired resonance signals are proportional to the amount of the associated compounds that is present within the tissue. As such, $^1\text{H-MRS}$ is deemed to be a quantitative method. Indeed, $^1\text{H-MRS}$ of the human heart has been used in various cross-sectional studies, e.g., reporting on myocardial creatine depletion in myocardial infarction³ and heart failure,⁴ and in longitudinal studies of myocardial triglyceride content, e.g., with nutritional interventions in normal volunteers,^{5,6} with endurance exercise,⁷ and with therapeutic interventions in patients, such as type 2 diabetes⁸ and aortic stenosis.⁹

Localized $^1\text{H-MRS}$ of the heart is challenging. Surrounding tissue can contaminate the myocardial signal, and air-filled lungs and flowing blood in the ventricles perturb the magnetic field homogeneity that is required for high sensitivity and adequate signal localization. These issues are further exacerbated by cardiac and respiratory motion. Several approaches that alleviate these issues for localized $^1\text{H-MRS}$ of the human heart have been proposed.² Adequate performance of a measurement technique requires precision and accuracy. *Precision* can be represented by the method's repeatability, i.e., how closely subsequent within-subject measurements agree. For measurements of in vivo myocardial triglyceride content with $^1\text{H-MRS}$, repeatability in terms of the within-subject coefficient of variation has been reported to be as low as 5% at 1.5 T⁵ and 3 T.¹⁰ Measurement repeatability for myocardial total creatine content at 3 T has not been reported. There are large discrepancies between the various reports on how the reported repeatability was estimated^{4,5} and whether this reflected intrasession or intersession repeatability of the measurements,^{11,12} inevitably leading to variations in the reported repeatability that was achieved with various $^1\text{H-MRS}$ methods (Table 1). *Accuracy* can be estimated by how well measurements agree with an external validation. Such validations are complicated and would require biochemical assays in tissue samples that are obtained from the same region from which the localized $^1\text{H-MRS}$ data were

acquired. Such studies have been conducted for human skeletal muscle²³ and liver,²⁴ but thorough validations for measurements in the human heart are lacking. Myocardial creatine measurements with $^1\text{H-MRS}$ have only been validated in dogs.³ Reported attempts on a small number of human tissue samples ($n \leq 10$) involved high-field NMR¹² or histology⁹ and did not include any biochemical assays of triglyceride content (Table 2). Validations of in vivo measurements with $^1\text{H-MRS}$ of the human heart against conventional invasive techniques are required to establish and confirm that $^1\text{H-MRS}$ is indeed a quantitative method for noninvasive assessments of myocardial tissue metabolite content.

Thus, the purpose of this work was to determine measurement precision and accuracy of myocardial total creatine and triglyceride content with $^1\text{H-MRS}$ of the human heart at 3 T.

Materials and Methods

The work in normal volunteers was performed according to recommendations by the local institutional review board (W15_373; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands). The validation study in patients scheduled for open-heart surgery was approved by the local institutional review board (NL52084.018.15; Academic Medical Center). All participants provided written informed consent.

$^1\text{H-MRS}$ Protocol

All subjects underwent a cardiac MR protocol with $^1\text{H-MRS}$ of the myocardial interventricular septum using a prospectively ECG-triggered respiratory-gated free-breathing single-voxel point-resolved spectroscopy (PRESS) sequence as introduced previously.¹⁰ All examinations were performed with a 3 T MR system (Ingenua, software release 5.1.8; Philips, Best, The Netherlands). Subjects were positioned supine with ECG and respiration sensors connected. After scout imaging, standard retrospectively ECG-triggered cinematographic image series were acquired during breathholds to obtain long-axis views and a contiguous stack of short-axis views covering the left ventricle (LV) from apex to base. Subsequently, an $8\text{--}15 \times 20\text{--}30 \times 20\text{--}30 \text{ mm}^3$ voxel (triglyceride-methylene at 1.30 ppm on-resonance) was carefully positioned in the interventricular septum (Fig. 1) at the location corresponding to 200 msec after detection of the R-wave in the ECG signal,

TABLE 1. Literature Reports on Proton Magnetic Resonance Spectroscopy (¹H-MRS) Measurement Repeatability in the Human Heart

	Year of Publication	Field Strength (T)	Number of Subjects (n)	Within-Subject CV (%)	Methodological Repeatability
<i>Total creatine</i>					
Felblinger et al ¹³	1999	1.5	9	10 ^a	Intersession
Nakae et al ⁴	2003	1.5	8	7.4	Not defined
This work	2021	3	16	19.8	Intrasession
This work	2021	3	16	21.3	Intersession
<i>Triglyceride</i>					
Felblinger et al ¹³	1999	1.5	9	13 ^a	Intersession
Szczepaniak et al ¹¹	2003	1.5	6	17	Intrasession and intersession combined
Reingold et al ⁵	2005	1.5	6	5	Intersession ^b
Kankaanpää et al ¹⁴	2006	1.5	9	17	Intrasession
van der Meer et al ¹⁵	2007	1.5	20	17.9	Intersession
O'Connor et al ¹⁶	2009	1.5	11	9	Not defined
O'Connor et al ¹²	2011	1.5	16	6.9	Intrasession and intersession combined
Rial et al ¹⁷	2011	3	15	19	Intrasession ^c
Weiss et al ¹⁸	2012	1.5 ^d	12	21	Intersession
Weiss et al ¹⁹	2014	1.5	5	11	Not defined
Ith et al ²⁰	2014	3	8	6.3 ^e	Intersession
de Heer et al ¹⁰	2016	3	8	5	Intrasession
de Heer et al ¹⁰	2016	3	7	6.5	Intersession
Gastl et al ²¹	2019	1.5	15	5.2	Intrasession
Gastl et al ²²	2019	1.5	10	9.5	Not defined
This work	2021	3	16	21.3	Intrasession
This work	2021	3	16	18.7	Intersession

^aCoefficient of variation (CV) reported after exclusion of spectra with “inferior quality.”

^bSessions were separated by a 90-days interval.

^cCV reported for same voxel location, but with reference and calibration scans invalidated and re-calibrated between consecutive scans.

^dUsing echo-planar spectroscopic imaging.

^eCV for triglyceride content quantified with triglyceride/creatine ratios (which was “essentially identical” when referenced to water), total creatine/water ratios not reported.

ensuring that the chemical-shift displaced voxel for total creatine at 3.02 ppm remained within the myocardial tissue as well as within the shim volume (20–30 × 40 × 50 mm³). Voxel size was adjusted to septal wall thickness. Multiple optimizations to improve suppression trains (MOIST; bandwidth 220 Hz centered on water at 4.7 ppm)²⁶ water-suppressed spectra (8 × 8 acquisitions; number of points, 1024; bandwidth, 1500 Hz) were acquired at a fixed

echo time (TE) of 40 msec and a long repetition time (TR) of >6 seconds to minimize partial saturation effects. Acquisition of the water-suppressed spectra was interleaved with acquisitions of 8 unsuppressed water spectra at a TR of >9 seconds (water at 4.7 ppm on-resonance) to obtain fully relaxed water signals from a voxel identical in size and position to the voxel for the water-suppressed acquisitions. Signals were stored separately and

TABLE 2. Literature Reports on Proton Magnetic Resonance Spectroscopy (¹H-MRS) Measurement Validation in the Human Heart

	Year of Publication	¹ H-MRS Method	Number of Samples (n)	Correlation Coefficient (r)	Method of Validation
<i>Total creatine</i>					
Bottomley and Weiss ³	1998	Bottomley et al ²⁵	12	Not reported	Fluorometric assay of total creatine in ex vivo canine myocardium
This work	2021	de Heer et al ¹⁰	22	0.44	Spectrophotometric assay of total creatine in tissue samples from patients
<i>Triglyceride</i>					
O'Connor et al ¹²	2011	O'Connor et al ¹⁶	6	0.91	400 MHz magic angle spinning NMR spectroscopy in endomyocardial biopsies from heart-transplanted patients
O'Connor et al ¹²	2011	O'Connor et al ¹⁶	8	0.98	600 MHz high-resolution NMR spectroscopy in endomyocardial biopsies from heart-transplanted patients
Mahmod et al ⁹	2013	Rial et al ¹⁷	10	0.66 ^a	Histology with Oil Red O-staining in biopsies from patients
This work	2021	de Heer et al ¹⁰	20	0.50	Colorimetric assay of triglyceride in tissue samples from patients

^aCorrelation not shown in the study by Mahmod et al.⁹

processed offline prior to myocardial metabolite content quantification.

Repeatability in Normal Volunteers

Volunteers (male/female, 8/8) underwent the MR exam protocol as described above. To test intrasession repeatability, ¹H-MRS acquisition was repeated by copying and executing the same scan directly after the first acquisition. Afterward, the volunteer was removed from the magnet and briefly exited the scanner room, after which the process was repeated immediately in a second MR examination of the same volunteer for an assessment of intersession repeatability. The entire MR protocol was repeated and included subject repositioning, scout imaging, voxel positioning, B₀ shimming, and RF power optimization. The procedure took approximately 1 hour to complete, minimizing any metabolic or physiological variation between scans.

Validation in Patients

We recruited 26 patients with a clinical indication for open-heart surgery at the Departments of Cardiology and Cardiothoracic Surgery at the Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands between April 2016 and March 2020. Patients were eligible if they had severe aortic valve

stenosis and were scheduled for surgical aortic valve replacement (AVR), or if they had hypertrophic obstructive cardiomyopathy and were scheduled for septal myectomy. Exclusion criteria were the presence of any non-MR compatible implants and other contraindications for MR examination. All participants underwent the MR protocol as described above. In addition, venous blood samples were collected just prior to MR examination and processed immediately according to the standard blood panel assays. Within 1 week after MR examination, myocardial tissue samples were collected intraoperatively, either via biopsies of the LV endocardial septum during surgical AVR or via septal myectomy through Morrow's procedure.²⁷ Samples collected via biopsies in patients who underwent AVR weighed 11.9 ± 5.1 mg wet weight. More tissue could be obtained from patients undergoing septal myectomy, yielding larger samples of 32.5 ± 21.1 mg wet weight. Any fibrotic tissue was removed upon collection, and tissue samples were immediately snap-frozen in liquid nitrogen and stored at -80°C until further analyses.

MR Data Analyses

¹H-MRS. Spectral fitting for signal quantification was performed in the time domain using the AMARES fitting routine in jMRUI²⁸ as




FIGURE 1: Localized ^1H -MRS of the human heart. A PRESS voxel (triglyceride-methylene at 1.30 ppm on-resonance for water-suppressed spectra, and water at 4.7 ppm on-resonance for unsuppressed spectra; other box) was carefully positioned in the interventricular septum at the location corresponding to 200 msec after detection of the R-wave in the ECG signal, ensuring that the chemical-shift displaced voxel for total creatine at 3.02 ppm (white box) remained within the myocardial tissue as well as within the shim volume (green box). Repeatability assessments were performed in men ($n = 8$; group mean spectrum in blue) and women ($n = 8$; red) and yielded three spectra per subject ($n = 8 \times 3 = 24$; gray). Peaks of trimethylamine-containing compounds (TMA; 3.2 ppm), total creatine-methyl (tCr-CH₃; 3.0 ppm), triglyceride-methylene (TG-CH₂-)_n at 1.3 ppm, and triglyceride-methyl (TG-CH₃; 0.9 ppm) are indicated. All spectra are scaled relative to the unsuppressed water signal acquired from the same voxel (other box).

described in detail in the Supporting Information. Myocardial total creatine content was quantified as the percentage of the total creatine-methyl signal amplitude of the unsuppressed water signal amplitude. Myocardial triglyceride content was estimated as the percentage of the sum of the triglyceride-methylene and triglyceride-

methyl signal amplitudes divided by the unsuppressed water signal amplitude.

CINEMATOGRAPHIC MRI. Heart function and morphology were assessed using quantitative analyses of the cinematographic




FIGURE 2: Precision. Bland-Altman analyses of in vivo myocardial total creatine content (a) and myocardial triglyceride content (b) measured with localized ^1H -MRS in men (blue symbols, $n = 8$) and women (red symbols, $n = 8$). The intersession repeatability coefficient for myocardial total creatine content was 41.8% with a mean value of $0.083\% \pm 0.020\%$ of the total water signal, and 36.7% for myocardial triglyceride content with a mean value of $0.35\% \pm 0.13\%$ of the total water signal. Dashed red lines represent the 95% confidence interval at 1.96 times the standard deviation of the differences between the repeated measurements around the mean difference between consecutive measurements (green solid line).




FIGURE 3: Localized ^1H -MRS of the heart in patients scheduled for surgical aortic valve replacement (AVR; $n = 13$; group mean spectrum in purple) and in patients scheduled for septal myectomy ($n = 9$; orange). Note the variability for myocardial triglyceride content between subjects, illustrated by differences in triglyceride-methylene signal amplitudes at 1.30 ppm in the individual spectra (gray). Peaks of trimethylamine-containing compounds (TMA; 3.2 ppm), total creatine-methyl (tCr-CH₃; 3.0 ppm), triglyceride-methylene (TG-CH₂-)_n at 1.3 ppm, and triglyceride-methyl (TG-CH₃; 0.9 ppm) are indicated. All spectra are scaled relative to the unsuppressed water signal acquired from the same voxel (ocher), which is identical to the scaling used in Fig. 1.

MRI series acquired in patients. Endocardial and epicardial contours of the LV were manually drawn by an experienced investigator (A.J. B.; 12 years experience) in QMass 8.1 (Medis medical imaging systems BV, Leiden, The Netherlands), and used to quantify end-diastolic (EDV) and end-systolic (ESV) LV volumes, LV stroke volume (SV), LV ejection fraction (EF), LV cardiac output, LV global longitudinal strain (GLS), and LV myocardial mass.

Biochemical Assays

TOTAL CREATINE ASSAY. Tissue samples were weighed and freeze-dried overnight, and then weighed again to estimate tissue water content. The myocardial total creatine concentration ($\mu\text{mol/g}$ wet weight) was measured with an enzymatic spectrophotometric assay²⁹ as described in detail in the Supporting Information.

TRIGLYCERIDE ASSAY. Total myocardial triglyceride concentration ($\mu\text{mol/g}$ wet weight) was determined biochemically via colorimetric quantification as described previously,³⁰ with minor modifications (Supporting Information).

Statistical Analyses

Data are presented as mean \pm standard deviation (SD). Intrasession and intersession repeatability of localized ^1H -MRS measurements was assessed using Bland-Altman analyses of the myocardial total creatine and triglyceride content quantifications.³¹ The repeatability coefficient is given by 1.96 times the SD of the differences between the repeated measurements and is expressed as a percentage of the mean value. The 95% confidence interval is defined as the repeatability coefficient offset by the mean difference between consecutive

measurements. The within-subject coefficient of variation (CV) was determined as described by Bland and Altman.³¹ Regression analyses were performed using MATLAB (The MathWorks, Inc., Natick, MA, USA) assuming a relative equal weighting of error between a linear model fit and in vivo ^1H -MRS measurements and biochemical assays. Covariance matrices for the slope and intercept parameters were estimated as described by Landaw and DiStefano,³² and used to determine 90% confidence bounds on the linear model fits. Differences between groups were tested with two-sided Student's *t*-tests. The level of significance was set at $P < 0.05$.

Results

Precision

The men in our cohort of normal volunteers were slightly older than the women (31.3 ± 3.3 vs. 27.5 ± 1.8 years; $P < 0.05$), and their height (1.87 ± 0.07 vs. 1.70 ± 0.07 m; $P < 0.05$) and body weight (81.1 ± 8.7 vs. 61.1 ± 6.3 kg; $P < 0.05$) were higher, which translated in a somewhat higher body mass index (BMI) for men compared to women (23.3 ± 1.7 vs. 21.0 ± 1.6 kg/m²; $P < 0.05$). Overall, water linewidth was similar in men and women (13.8 ± 2.8 vs. 13.1 ± 2.4 Hz; $P = 0.351$). In addition, water linewidth correlated with heart rate during MR examination (16 volunteers \times 2 sessions; $n = 32$, $r = 0.39$; $P < 0.05$), suggesting that B₀ shimming was better at lower heart rates. Localized ^1H -MR spectra were obtained from the interventricular septum, and revealed distinct peaks of the total creatine-methyl resonance (3.02 ppm) and triglyceride-methylene (1.3 ppm) and -methyl (0.9 ppm)




FIGURE 4: Accuracy. Regression analyses of in vivo myocardial total creatine content (a) and triglyceride content (b) measured with localized ¹H-MRS against ex vivo myocardial total creatine concentration ($n = 22$, $r = 0.44$; $P < 0.05$) and triglyceride concentration ($n = 20$, $r = 0.50$; $P < 0.05$) determined biochemically in tissue samples obtained from the same subjects. Dashed lines indicate 90% confidence bounds of the linear model fits (solid lines). AVR, aortic valve replacement.

resonances (Fig. 1). Overall, the relative Cramér Rao Lower Bound (CRLB) was $4.8\% \pm 2.5\%$ for the fit of total creatine, and $3.3\% \pm 2.6\%$ for triglyceride-methylene. Myocardial total creatine content was higher in men than in women ($0.094\% \pm 0.021\%$ vs. $0.075\% \pm 0.018\%$ of the total water signal; $P < 0.05$). The same was found for myocardial triglyceride content ($0.44\% \pm 0.11\%$ vs. $0.26\% \pm 0.09\%$ of the total water signal; $P < 0.05$). The intrasession repeatability coefficient for myocardial total creatine content was 38.8% at a mean of $0.084\% \pm 0.018\%$ of the total water signal with a mean difference between consecutive measurements of $0.005\% \pm 0.017\%$ of the total water signal. The intra-session within-subject CV of myocardial total creatine content was 19.8% (Table 1). The intrasession repeatability coefficient for myocardial triglyceride content was 41.8% at a mean of $0.35\% \pm 0.12\%$ of the total water signal with a mean difference between measurements of $0.02\% \pm 0.08\%$ of the total water signal. The intrasession within-subject CV of myocardial triglyceride content was 21.3% (Table 1). Intersession repeatability was similar to intrasession repeatability for both measurements, with a repeatability coefficient of 41.8% for myocardial total creatine content (Fig. 2(a)) and 36.7% for myocardial triglyceride content (Fig. 2(b)). Within-subject CVs were 21.3% and 18.7%, respectively (Table 1). These data indicate that at 95% confidence of detecting a (patho)physiological change rather than an effect of measurement error, the present approach for ¹H-MRS can detect changes of approximately >40% in myocardial total creatine or myocardial triglyceride content between repeated measurements in a single subject.

Accuracy

Out of a total of 26 patients scheduled for open-heart surgery that we recruited for this study, three patients indicated

experiencing shortness-of-breath, dizziness, or claustrophobia during their MR examination, upon which the session was aborted before the acquisition of ¹H-MRS data. No endomyocardial biopsies were performed in these patients. In one patient, no biopsy could be taken due to insufficient access to the septum during surgery. As such, complete MR datasets with associated tissue samples of 13 patients who underwent AVR and of 9 patients with hypertrophic cardiomyopathy who underwent septal myectomy were available for analyses (Fig. 3). Characteristics, blood panel results and MR results for both groups are reported in the Supporting Information Table.

Water linewidth was similar for AVR and myectomy patients (14.7 ± 2.4 vs. 13.4 ± 3.6 Hz; $P = 0.337$) and was similar to water linewidths achieved in volunteers ($P = 0.289$). Myocardial total creatine content measured with ¹H-MRS was similar for AVR and myectomy patients ($0.095\% \pm 0.021\%$ vs. $0.089\% \pm 0.027\%$ of the total water signal; $P = 0.575$) and was well within the normal range that we established in volunteers. Myocardial triglyceride content was $0.67\% \pm 0.36\%$ and $0.50\% \pm 0.18\%$ of the total water signal ($P = 0.223$) for AVR and myectomy patients, respectively, which was above the normal range, and had a larger variability between subjects than in normal volunteers.

Samples of 22 patients were available for biochemical assays of the myocardial total creatine concentration. Because endomyocardial biopsy did not yield enough tissue from two patients that underwent AVR, myocardial triglyceride concentration was determined in samples of 20 patients. Tissue water content, measured by comparing sample wet weights with sample dry weights, was $81.9\% \pm 3.7\%$. Myocardial total creatine concentrations were similar for AVR and myectomy samples: 7.6 ± 2.4 vs. 6.4 ± 2.3 $\mu\text{mol/g}$ wet

weight ($P = 0.290$). Importantly, these ex vivo myocardial total creatine concentrations determined with biochemical assays in tissue samples correlated with the in vivo myocardial total creatine content measured with $^1\text{H-MRS}$ in the same subjects: $n = 22$, $r = 0.44$; $P < 0.05$ (Fig. 4(a)). Myocardial triglyceride concentrations were highly variable between subjects and were 8.7 ± 7.4 and 3.9 ± 2.8 $\mu\text{mol/g}$ wet weight ($P < 0.05$) for AVR and myectomy samples, respectively. The ex vivo myocardial triglyceride concentrations determined via biochemical assays in tissue samples correlated with the in vivo myocardial triglyceride content measured with $^1\text{H-MRS}$ in the same subjects: $n = 20$, $r = 0.50$; $P < 0.05$ (Fig. 4(b)). These results show that the present approach for $^1\text{H-MRS}$ can accurately estimate in vivo myocardial total creatine and triglyceride content.

Heart Function and Morphology

Functional and morphological parameters for hearts of patients are reported in the Supporting Information Table. LV SV (74 ± 12 vs. 92 ± 17 mL; $P < 0.05$) and LV EF ($57.8\% \pm 13.1\%$ vs. $67.9\% \pm 6.4\%$; $P < 0.05$) were higher in myectomy patients compared to AVR patients. LV GLS in myectomy patients was also larger compared to AVR patients ($-17.8\% \pm 6.8\%$ vs. $-24.2\% \pm 4.4\%$; $P < 0.05$). In absolute sense, the LV EDV and LV myocardial mass were similar in both groups, translating in a similar LV mass-to-volume ratio (Supporting Information Table). With a difference in BSA ($P < 0.05$), LV EDV indexed to BSA (63.4 ± 10.1 vs. 72.7 ± 8.8 mL/m²; $P < 0.05$) and LV myocardial mass indexed to BSA (79.3 ± 13.6 vs. 95.5 ± 15.5 g/m²; $P < 0.05$) were much higher in patients who were scheduled for septal myectomy than in those scheduled for AVR, reflecting hypertrophic cardiomyopathy in the former. Myocardial total creatine and triglyceride content measured with $^1\text{H-MRS}$ did not correlate with any of the functional or morphologic parameters, or with any of the circulating metabolite levels measured in blood collected just prior to MR examination. The relatively high Hb1Ac values, a marker for hyperglycemia, did not reach a significant positive correlation with myocardial triglyceride content measured with $^1\text{H-MRS}$ ($n = 22$, $r = 0.38$; $P = 0.077$).

Discussion

This work shows that the precision in terms of measurement repeatability of localized $^1\text{H-MRS}$ is sufficient to detect (patho)physiological changes of myocardial total creatine and triglyceride content of $>40\%$ with 95% confidence in a single subject. Moreover, we established the accuracy of $^1\text{H-MRS}$ by demonstrating a good agreement between measurements of myocardial total creatine and triglyceride content quantified by non-invasive $^1\text{H-MRS}$ and biochemical assays of metabolite concentrations in myocardial tissue samples obtained intra-operatively from the same patients.

Precision

The repeatability of the $^1\text{H-MRS}$ approach used in the present study is comparable to previously reported work (Table 1), with the CV for myocardial triglyceride content on the high end of what has been reported for measurements at 1.5 T¹⁵ and 3 T¹⁷ (Table 1). Importantly, its intrasession and intersession repeatability were very similar for myocardial total creatine content as well as for triglyceride content, suggesting that subject repositioning and initial voxel positioning are not the dominant factors contributing to within-subject variation. Instead, we suggest that despite triggering signal acquisitions to the ECG R-wave, physiological variations in heart rate lead to small displacements of the interventricular septum with respect to the voxel positioned for $^1\text{H-MRS}$ acquisition, and consequently lead to myocardial signal fluctuations.^{10,33} Besides such variations in signal acquisition, measurement errors can arise in signal quantification through spectral fitting. Using a dedicated fitting model based on biochemical, physical, and empirical prior knowledge, and aided by the high B_0 shim quality³⁴ that yielded well-resolved resonance peaks, we achieved CRLBs of $<10\%$ for essentially all fits. Note that we did not use high relative CRLBs as a criterion to exclude any spectra, in order to avoid bias toward higher tissue metabolite content.³⁵ Nonetheless, with the CRLB being the lower threshold of the fitting error, such fitting errors likely contributed markedly to within-subject variation. Together, these results emphasize the importance of adequate localization of signal acquisition and B_0 shimming³⁴ as well as an appropriate spectral fitting approach for precise quantitative $^1\text{H-MRS}$ readouts of the human heart.

Accuracy

We established the accuracy of in vivo myocardial total creatine and triglyceride content measurements with an optimized approach for localized $^1\text{H-MRS}$ of the human heart at 3 T¹⁰ in a direct comparison with biochemical assays of myocardial tissue samples collected from more than 20 patients. We assumed a homogeneous spatial distribution of myocardial total creatine and triglyceride content in these nonischemic patients, and that the small tissue samples collected from the LV endocardial septum would reflect the content within the relatively large voxel required for localized $^1\text{H-MRS}$ of the septum. Indeed, $^1\text{H-MRS}$ provides an accurate noninvasive measure of in vivo tissue triglyceride content, which was previously demonstrated for human skeletal muscle²³ and liver.²⁴ Importantly, we have now extended this approach to the technologically challenging application of $^1\text{H-MRS}$ in the human heart, and moreover, we provide an accuracy assessment of in vivo myocardial total creatine content as well. Even with the relatively high CVs that we found in the present study, our results now offer confirmation that $^1\text{H-MRS}$ is a reliable tool to noninvasively assess

myocardial tissue metabolite content, one that has been used in many studies for over 25 years for investigations of cardiac physiology and intervention efficacy in health and disease.²

Pathophysiology

It has been recognized since the 1930s that myocardial total creatine content can be lower in the failing heart than in the healthy heart.³⁶ As such, an accurate estimate of the total myocardial creatine content is crucial for a meaningful interpretation of commonly used phosphocreatine-to-ATP ratio measured with phosphorus-31 MRS as a parameter that reflects the myocardial energy status.³⁷ As expected, in this cohort of patients with severe aortic valve stenosis or hypertrophic cardiomyopathy who had preserved systolic function, we did not observe any correlations of in vivo myocardial creatine content with heart function or with myocardial mass. Indeed, the myocardial total creatine content in patients was similar to volunteers. Myocardial triglyceride content in patients was nearly twice as high as in volunteers. Elevated myocardial triglyceride content has been related to decreased myocardial function in calorie-restricted healthy volunteers⁶ and type 2 diabetes.³⁸ Yet, in vivo myocardial triglyceride content did not correlate with any functional or morphological parameters in the present cohort of patients with preserved systolic function. This suggests that measurements in larger cohorts with a broader range of (diabetic) cardiomyopathies are required to establish such relationships.

Limitations

We did not convert our estimates of in vivo myocardial total creatine and triglyceride content into absolute concentrations. Doing so requires a number of assumptions that we could not verify in vivo, including tissue water content, myocardial T₂ relaxation time constants for creatine-methyl and triglyceride signals, and the chemical composition of myocardial triglycerides (e.g., fatty acid chain lengths and degree of saturation). Assuming myocardial T₂ values of creatine-methyl and water to be similar to those in skeletal muscle at 3 T (135 msec and 30 msec, respectively³⁹), 55.5 M concentration of water, a 3-hydrogen nuclei signal for creatine-methyl and a 2-hydrogen signal for water, a tissue water content of 0.82 liter/kg (this work) and an in vivo myocardial total creatine content of 0.09% of the total water signal measured at a TE of 40 msec and a long TR for fully relaxed conditions (this work), we would arrive at an in vivo myocardial total creatine concentration estimate of 9.7 μmol/g wet weight. This value appears to be twofold lower than reported values for in vivo ¹H-MRS estimates ranging from 20 μmol/g wet weight¹⁸ up to 29 μmol/g wet weight,^{3,4} but is in good agreement with our ex vivo estimates of ~7 μmol/g wet weight determined biochemically in biopsies, and is more consistent with early reports on normal human

myocardium (9.3 μmol/g wet weight³⁶). Following similar calculations and assuming a T₂ value of 90 msec for triglyceride-methylene,³⁹ a 68.6-hydrogen nuclei signal for triglyceride-methylene⁴⁰ and a 3-hydrogen nuclei signal per triglyceride-methyl group, the in vivo myocardial triglyceride concentration estimate would be 2.9 μmol/g wet weight. This is on the low end of the biochemical estimates in tissue samples (4–9 μmol/g wet weight) and may be attributed to the assumed number of methylene hydrogens per triglyceride that could be an overestimation with unsaturated bonds not being taken into account. Furthermore, tissue samples were collected intra-operatively on a different day after the MR exam. Indeed, as we^{6,7} and others²⁰ have shown previously, the myocardial triglyceride pool is highly dynamic, and diurnal or nutritional differences between MR examination and surgery may contribute to discrepancies between measurements. Notably, fasting has been shown to elevate myocardial triglyceride content.⁵ Patients were fasted for >9 hours prior to surgery, which could explain the higher myocardial triglyceride content determined biochemically in tissue samples compared to those found with ¹H-MRS. Myocardial total creatine content is considered to be more stable, which is reflected by the good agreement between in vivo ¹H-MRS measurements and ex vivo assays of myocardial tissue collected during surgery.

Conclusion

We have validated the use of localized ¹H-MRS of the human heart at 3 T for quantitative assessments of in vivo myocardial tissue metabolite content by establishing measurement precision and accuracy. Evidenced by correlations between in vivo myocardial total creatine and triglyceride content measured with ¹H-MRS and ex vivo biochemical assays in myocardial tissue samples from the same subjects, we confirmed that ¹H-MRS is a quantitative tool for noninvasive assessments of myocardial tissue metabolite content. Such validations provide valuable guidance for quantitative interpretations and comparisons of future and past ¹H-MRS studies of the human heart.

References

- den Hollander JA, Evanochko WT, Pohost GM. Observation of cardiac lipids in humans by localized ¹H magnetic resonance spectroscopic imaging. *Magn Reson Med* 1994;32:175-180.
- Faller KME, Lygate CA, Neubauer S, Schneider JE. ¹H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism. *Heart Fail Rev* 2013;18:657-668.
- Bottomley PA, Weiss RG. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. *Lancet* 1998;351:714-718.
- Nakae I, Mitsunami K, Omura T, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. *J Am Coll Cardiol* 2003;42:1587-1593.
- Reingold JS, McGavock JM, Kaka S, Tillery T, Victor RG, Szczepaniak LS. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: Reproducibility and

- sensitivity of the method. *Am J Physiol Endocrinol Metab* 2005;289:E935-E939.
6. van der Meer RW, Hammer S, Smit JWA, et al. Short-term caloric restriction induces accumulation of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects. *Diabetes* 2007;56:2849-2853.
 7. Aengevaeren VL, Froeling M, van den Berg-Faay S, et al. Marathon running transiently depletes the myocardial lipid pool. *Physiol Rep* 2020;8:e14543.
 8. Paiman EHM, van Eyk HJ, van Aalst MMA, et al. Effect of liraglutide on cardiovascular function and myocardial tissue characteristics in type 2 diabetes patients of South Asian descent living in The Netherlands: A double-blind, randomized, placebo-controlled trial. *J Magn Reson Imaging* 2020;51:1679-1688.
 9. Mahmod M, Bull S, Suttie JJ, et al. Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosis. *Circ Cardiovasc Imaging* 2013;6:808-816.
 10. de Heer P, Bizino MB, Lamb HJ, Webb AG. Parameter optimization for reproducible cardiac ¹H-MR spectroscopy at 3 Tesla. *J Magn Reson Imaging* 2016;44:1151-1158.
 11. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: *in vivo* evaluation by localized proton spectroscopy and cardiac imaging. *Magn Reson Med* 2003;49:417-423.
 12. O'Connor RD, Xu J, Ewald GA, et al. Intramyocardial triglyceride quantification by magnetic resonance spectroscopy: *in vivo* and *ex vivo* correlation in human subjects. *Magn Reson Med* 2011;65:1234-1238.
 13. Felblinger J, Jung B, Slotboom J, Boesch C, Kreis R. Methods and reproducibility of cardiac/respiratory double-triggered ¹H-MR spectroscopy of the human heart. *Magn Reson Med* 1999;42:903-910.
 14. Kankaanpää M, Lehto H-R, Pärkkä JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: Relationship to left ventricular function and serum free fatty acid levels. *J Clin Endocrinol Metab* 2006;91:4689-4695.
 15. van der Meer RW, Doornbos J, Kozerke S, et al. Metabolic imaging of myocardial triglyceride content: reproducibility of ¹H MR spectroscopy with respiratory navigator gating in volunteers. *Radiology* 2007;245:251-257.
 16. O'Connor RD, Bashir A, Cade WT, Yarasheski KE, Gropler RJ. ¹H-magnetic resonance spectroscopy for quantifying myocardial lipid content in humans with the cardiometabolic syndrome. *J Clin Hypertens* 2009;11:528-532.
 17. Rial B, Robson MD, Neubauer S, Schneider JE. Rapid quantification of myocardial lipid content in humans using single breath-hold ¹H MRS at 3 Tesla. *Magn Reson Med* 2011;66:619-624.
 18. Weiss K, Martini N, Boesiger P, Kozerke S. Metabolic MR imaging of regional triglyceride and creatine content in the human heart. *Magn Reson Med* 2012;68:1696-1704.
 19. Weiss K, Summermatter S, Stoeck CT, Kozerke S. Compensation of signal loss due to cardiac motion in point-resolved spectroscopy of the heart. *Magn Reson Med* 2014;72:1201-1207.
 20. Ith M, Stettler C, Xu J, Boesch C, Kreis R. Cardiac lipid levels show diurnal changes and long-term variations in healthy human subjects. *NMR Biomed* 2014;27:1285-1292.
 21. Gastl M, Peereboom SM, Fuetterer M, et al. Cardiac- versus diaphragm-based respiratory navigation for proton spectroscopy of the heart. *MAGMA* 2019;32:259-268.
 22. Gastl M, Peereboom SM, Fuetterer M, et al. Retrospective phase-based gating for cardiac proton spectroscopy with fixed scan time. *J Magn Reson Imaging* 2019;50:1973-1981.
 23. Howald H, Boesch C, Kreis R, et al. Content of intramyocellular lipids derived by electron microscopy, biochemical assays, and ¹H-MR spectroscopy. *J Appl Physiol* 2002;92:2264-2272.
 24. Krššák M, Hofer H, Wrba F, et al. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by ¹H magnetic resonance spectroscopy. *Eur J Radiol* 2010;74:e60-e66.
 25. Bottomley PA, Lee YH, Weiss RG. Total creatine in muscle: Imaging and quantification with proton MR spectroscopy. *Radiology* 1997;204:403-410.
 26. Murdoch JB, Lampman DA. Beyond WET and DRY: optimized pulses for water suppression. In: Proceedings of the 12th Annual Meeting of SMRM, New York, 1993 (abstract 1191).
 27. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and post-operative assessments in 83 patients. *Circulation* 1975;52:88-102.
 28. Vanhamme L, van den Boogaart A, van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. *J Magn Reson* 1997;129:35-43.
 29. Fiolet JWT, Baartscheer A, Schumacher CA, Coronel R, ter Welle HF. The change of the free energy of ATP hydrolysis during global ischemia and anoxia in the rat heart. Its possible role in the regulation of transsarcolemmal sodium and potassium gradients. *J Mol Cell Cardiol* 1984;16:1023-1036.
 30. Bakermans AJ, Geraedts TR, van Weeghel M, et al. Fasting-induced myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice is accompanied by impaired left ventricular function. *Circ Cardiovasc Imaging* 2011;4:558-565.
 31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;327:307-310.
 32. Landaw EM, DiStefano JJ 3rd. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. *Am J Physiol* 1984;246:R665-R677.
 33. Bakermans AJ, Abdurrahim D, Geraedts TR, Houten SM, Nicolay K, Prompers JJ. *In vivo* proton T₁ relaxation times of mouse myocardial metabolites at 9.4 T. *Magn Reson Med* 2015;73:2069-2074.
 34. Juchem C, Cudalbu C, de Graaf RA, et al. B₀ shimming for *in vivo* magnetic resonance spectroscopy: Experts' consensus recommendations. *NMR Biomed* 2020;e4350. <https://doi.org/10.1002/nbm.4350>
 35. Kreis R. The trouble with quality filtering based on relative Cramér-Rao lower bounds. *Magn Reson Med* 2016;75:15-18.
 36. Cowan DW. The creatine content of the myocardium of normal and abnormal human hearts. *Am Heart J* 1934;9:378-385.
 37. Bakermans AJ, Bazil JN, Nederveen AJ, et al. Human cardiac ³¹P-MR spectroscopy at 3 Tesla cannot detect failing myocardial energy homeostasis during exercise. *Front Physiol* 2017;8:939.
 38. Rijzewijk LJ, van der Meer RW, Smit JWA, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. *J Am Coll Cardiol* 2008;52:1793-1799.
 39. Krššák M, Mlynárik V, Meyerspeer M, Moser E, Roden M. ¹H NMR relaxation times of skeletal muscle metabolites at 3 T. *MAGMA* 2004; 16:155-159.
 40. Madden MC, van Winkle WB, Kirk K, Pike MM, Pohost GM, Wolkowicz PE. ¹H-NMR spectroscopy can accurately quantitate the lipolysis and oxidation of cardiac triacylglycerols. *Biochim Biophys Acta* 1993;1169:176-182.